1. Home
  2. SRDX vs NMAI Comparison

SRDX vs NMAI Comparison

Compare SRDX & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRDX
  • NMAI
  • Stock Information
  • Founded
  • SRDX 1979
  • NMAI 2021
  • Country
  • SRDX United States
  • NMAI United States
  • Employees
  • SRDX N/A
  • NMAI N/A
  • Industry
  • SRDX Medical/Dental Instruments
  • NMAI Investment Managers
  • Sector
  • SRDX Health Care
  • NMAI Finance
  • Exchange
  • SRDX Nasdaq
  • NMAI Nasdaq
  • Market Cap
  • SRDX 402.2M
  • NMAI 429.9M
  • IPO Year
  • SRDX 1998
  • NMAI N/A
  • Fundamental
  • Price
  • SRDX $41.40
  • NMAI $13.37
  • Analyst Decision
  • SRDX Buy
  • NMAI
  • Analyst Count
  • SRDX 3
  • NMAI 0
  • Target Price
  • SRDX $43.00
  • NMAI N/A
  • AVG Volume (30 Days)
  • SRDX 252.6K
  • NMAI 74.8K
  • Earning Date
  • SRDX 11-05-2025
  • NMAI 01-01-0001
  • Dividend Yield
  • SRDX N/A
  • NMAI 13.14%
  • EPS Growth
  • SRDX N/A
  • NMAI N/A
  • EPS
  • SRDX N/A
  • NMAI 0.64
  • Revenue
  • SRDX $120,801,000.00
  • NMAI N/A
  • Revenue This Year
  • SRDX N/A
  • NMAI N/A
  • Revenue Next Year
  • SRDX $3.38
  • NMAI N/A
  • P/E Ratio
  • SRDX N/A
  • NMAI $19.03
  • Revenue Growth
  • SRDX N/A
  • NMAI N/A
  • 52 Week Low
  • SRDX $25.87
  • NMAI $10.60
  • 52 Week High
  • SRDX $41.67
  • NMAI $12.55
  • Technical
  • Relative Strength Index (RSI)
  • SRDX 83.94
  • NMAI 64.45
  • Support Level
  • SRDX $26.00
  • NMAI $13.05
  • Resistance Level
  • SRDX $28.67
  • NMAI $13.31
  • Average True Range (ATR)
  • SRDX 0.94
  • NMAI 0.13
  • MACD
  • SRDX 1.54
  • NMAI 0.02
  • Stochastic Oscillator
  • SRDX 98.23
  • NMAI 95.65

About SRDX Surmodics Inc.

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.

Share on Social Networks: